Monday, September 10, 2018 5:55 AM
WEED, Inc. Forms WEED Israel (Cannabis) Ltd, WEED Australia Ltd, and Cannabis Institute of Australia...
TUCSON, AZ / ACCESSWIRE / September 10, 2018 / WEED, Inc. (OTC PINK: BUDZ) (the "Company" or "WEED"), has established WEED Israel (Cannabis) Ltd. as a wholly owned subsidiary of WEED Inc (USA). WEED Israel (Cannabis) Ltd. is currently in negotiations with major universities, hospitals, charitable organizations, Kibbutz, and private & public entities to create a true "SEED-TO-SALE" company from this Holy Land. WEED Israel's goal is to educate the medical community with treatments and therapies to stop opioid dependency for military and public, to service the Israeli domestic Cannabis medical market, WEED Israel (Cannabis) Ltd. plans to work closely with the Israeli Ministry of Health, to grow its cannabis export markets.
WEED Israel (Cannabis) Ltd. President/CEO Glenn E. Martin proclaims that "At least 50% of any profits from operations in Israel will remain in Israel to create/expand new medicinal therapies & treatments for the Israeli people suffering from ailments and opioid destruction. WEED Israel looks to establish the 'GOLD STANDARD' model to make sure Israel receives its fair share and not to be exploited by large Canna-pharma companies from overseas."
"Unique in the cannabis research world, Israel has been in the forefront of the industry since the early 1960's. We believe Israel can show the world that the dedication and hard work of its top researchers over the last few decades has created new Cannabis discoveries, including everything from delivery systems for humans and pets to creating new Cannabis Sativa strains to alleviate pain and ailments for human diseases," states Executive VP, Mr. Elliot Kwestel.
Mr. Kwestel, WEED Israel (Cannabis) Ltd.'s Director, Secretary and Executive VP for domestic and International development comments, "The cures are out there, we believe you'll find them in WEED."
WEED Australia Ltd., established in March 2017, was one of only a handful of cannabis companies in Australia at the time and the first and only subsidiary of a United States-based public company in Australia. WEED Australia Ltd.'s goal is an IPO in 2019. WEED Australia Ltd. formed its nonprofit division, The Cannabis Institute of Australia in March 2018, with the goal of creating (i) a Scientific Advisory Council to establish National protocols and procedures backed by scientific research to perfect strain specific, disease-specific treatments, therapies and prayed for cures, (ii)
a network of PHD's and doctors across Australia, from Brisbane & Perth, to educate and oversee clinical trials, protocols and procedures for both humans & animals, (iii) medical discoveries & products to conquer the opioid addiction with natural remedies. Educating MD's & naturopathic doctors, are key to implementing a National Cannabis Medical program, and (iv) Australia's finest export industry for cannabis and hemp products to maximize its curative power while minimizing its cost to the world.
WEED Inc (USA) is a fully reporting, PCAOB audited, Sarbanes-Oxley compliant, world-class cannabis corporation with corporate offices in Israel, Australia and United States of America.
WEED Inc. (BUDZ) established its wholly owned subsidiary; WEED Israel (Cannabis) Ltd. (2018). #515884567
WEED Australia Ltd. (2017) ACN: 617 827 764 and its wholly owned nonprofit arm;
The Cannabis Institute of Australia (C.I.A,) in Q1 2018. ACN:625 492 113
The Cannabis Institute is wholly owned by WEED Australia Ltd.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of WEED, Inc.'s securities, here or abroad, nor shall there be any sale of the shares of common stock in any state or country in which offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or country.
About WEED, Inc.
WEED, Inc. (OTCQB: BUDZ) is currently a USA-based fully reporting public company. WEED Inc. is a multi-national, multi-faceted, vertically-integrated world class Cannabis organization. WEED is structured as a holding company doing business through its divisions, wholly-owned subsidiaries, and strategically placed collaborative partners to achieve and promote our global brand. WEED is dedicated to its global goals and outreach across the full spectrum of the Cannabis industry to find treatments, therapies and medical cures utilizing the Cannabaceae plant family. WEED does not grow, harvest, produce, or sell any substance in violation of US Federal law under The Federal Controlled Substances Act, and meets all standards of international law for WEED, Inc. and its subsidiaries in foreign locations. For additional information about WEED, Inc., please visit www.WEEDInc.co
About Sangre AT, LLC
Sangre AT, LLC (dba "Sangre AgroTech") is a plant genomic research and breeding company comprised of top-echelon scientists with extensive expertise in genomic sequencing, genetics-based breeding, plant tissue culture, and plant biochemistry, utilizing the most advanced sequencing and analytical technologies and proprietary bioinformatics data systems available. For additional information about Sangre AgroTech, please visit www.sangreagrotech.com.
This release contains forward-looking statements. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects," "anticipates," "intends," "estimates," "plans," "potential," "possible," "probable," "believes," "seeks," "may," "will," "should," "could" or the negative of such terms or other similar expressions. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the Company's business, including that we have a limited operating history and very limited funds, are dependent upon key personnel whose loss may adversely impact our business, some of our potential business activities, while believed to be compliant with applicable state law, may be illegal under federal law because they violate the Federal Controlled Substances Act, and we may be subject to the risks related to the cost, delays and uncertainties associated with potential future scientific research, product development, clinical trials and the regulatory approval process. We may not be able to enter into binding agreements related to the subject matter of this press release on terms favorable to us or at all. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and the Company undertakes no to revise or update this release to reflect events or circumstances after the date hereof.
For more information, contact:
Glenn E. Martin at (520) 818-8582 or info@WEEDInc.co
SOURCE: WEED, Inc.